Ondine Biomedical Inc (OBI) - Net Assets
Based on the latest financial reports, Ondine Biomedical Inc (OBI) has net assets worth GBX3.49 Million GBX (≈ $424.53 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX14.40 Million ≈ $1.75K USD) and total liabilities (GBX10.91 Million ≈ $1.33K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OBI tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX3.49 Million |
| % of Total Assets | 24.23% |
| Annual Growth Rate | 3.84% |
| 5-Year Change | -88.23% |
| 10-Year Change | 1149.77% |
| Growth Volatility | 700.59 |
Ondine Biomedical Inc - Net Assets Trend (2001–2025)
This chart illustrates how Ondine Biomedical Inc's net assets have evolved over time, based on quarterly financial data. See Ondine Biomedical Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Ondine Biomedical Inc (2001–2025)
The table below shows the annual net assets of Ondine Biomedical Inc from 2001 to 2025. For live valuation and market cap data, see OBI stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX3.49 Million ≈ $424.53 |
-49.26% |
| 2024-12-31 | GBX6.88 Million ≈ $836.73 |
+229.83% |
| 2023-12-31 | GBX2.08 Million ≈ $253.68 |
-82.09% |
| 2022-12-31 | GBX11.64 Million ≈ $1.42K |
-60.74% |
| 2021-12-31 | GBX29.66 Million ≈ $3.61K |
+187.67% |
| 2020-12-31 | GBX-33.83 Million ≈ $-4.12K |
-29.74% |
| 2019-12-31 | GBX-26.07 Million ≈ $-3.17K |
-45.68% |
| 2018-12-31 | GBX-17.90 Million ≈ $-2.18K |
-173.34% |
| 2017-12-31 | GBX-6.55 Million ≈ $-796.70 |
-2445.38% |
| 2010-12-31 | GBX279.19K ≈ $33.97 |
-78.15% |
| 2009-12-31 | GBX1.28 Million ≈ $155.48 |
-4.44% |
| 2008-12-31 | GBX1.34 Million ≈ $162.71 |
-87.67% |
| 2007-12-31 | GBX10.84 Million ≈ $1.32K |
-34.64% |
| 2006-12-31 | GBX16.59 Million ≈ $2.02K |
+0.53% |
| 2005-12-31 | GBX16.50 Million ≈ $2.01K |
+7350.48% |
| 2003-08-31 | GBX-227.62K ≈ $-27.70 |
-58.87% |
| 2002-08-31 | GBX-143.28K ≈ $-17.43 |
-110.28% |
| 2001-08-31 | GBX1.39 Million ≈ $169.63 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ondine Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31470499700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX288.54 Million | 8269.56% |
| Other Comprehensive Income | GBX19.74 Million | 565.62% |
| Other Components | GBX10.54 Million | 302.09% |
| Total Equity | GBX3.49 Million | 100.00% |
Ondine Biomedical Inc Competitors by Market Cap
The table below lists competitors of Ondine Biomedical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tarku Resources Ltd
V:TKU
|
$916.81K |
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
$918.72K |
|
EJF Investments Ltd
LSE:EJFI
|
$918.79K |
|
Alveen
PA:MLALV
|
$920.96K |
|
SPOTLITE360 IOT SOLUTIONS
F:87A0
|
$916.43K |
|
Aker Horizons AS
OL:AKH
|
$915.32K |
|
Braemar Plc
LSE:BMS
|
$913.90K |
|
Geneuro SA
PA:GNRO
|
$911.56K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ondine Biomedical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,877,000 to 3,489,199, a change of -3,387,801 (-49.3%).
- Net loss of 29,588,760 reduced equity.
- Other comprehensive income increased equity by 19,735,762.
- Other factors increased equity by 6,465,197.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-29.59 Million | -848.01% |
| Other Comprehensive Income | GBX19.74 Million | +565.62% |
| Other Changes | GBX6.47 Million | +185.29% |
| Total Change | GBX- | -49.26% |
Book Value vs Market Value Analysis
This analysis compares Ondine Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1932.72x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 14.10x to 1932.72x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-08-31 | GBX1.03 | GBX14.50 | x |
| 2002-08-31 | GBX-0.11 | GBX14.50 | x |
| 2003-08-31 | GBX11.97 | GBX14.50 | x |
| 2005-12-31 | GBX0.41 | GBX14.50 | x |
| 2006-12-31 | GBX0.35 | GBX14.50 | x |
| 2007-12-31 | GBX0.20 | GBX14.50 | x |
| 2008-12-31 | GBX0.02 | GBX14.50 | x |
| 2009-12-31 | GBX0.01 | GBX14.50 | x |
| 2010-12-31 | GBX0.00 | GBX14.50 | x |
| 2017-12-31 | GBX-0.03 | GBX14.50 | x |
| 2018-12-31 | GBX-0.09 | GBX14.50 | x |
| 2019-12-31 | GBX-0.13 | GBX14.50 | x |
| 2020-12-31 | GBX-0.17 | GBX14.50 | x |
| 2021-12-31 | GBX0.15 | GBX14.50 | x |
| 2022-12-31 | GBX0.06 | GBX14.50 | x |
| 2023-12-31 | GBX0.01 | GBX14.50 | x |
| 2024-12-31 | GBX0.03 | GBX14.50 | x |
| 2025-12-31 | GBX0.01 | GBX14.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ondine Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -848.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1115.53%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 4.13x
- Recent ROE (-848.01%) is below the historical average (-260.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -5.26% | 0.00% | 0.00x | 1.04x | GBX-212.71K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-1.52 Million |
| 2003 | -0.52% | 0.00% | 0.00x | 0.00x | GBX-1.70 Million |
| 2005 | -51.74% | 0.00% | 0.00x | 1.05x | GBX-10.19 Million |
| 2006 | -72.10% | -738.91% | 0.09x | 1.11x | GBX-13.62 Million |
| 2007 | -121.30% | -819.56% | 0.12x | 1.20x | GBX-14.24 Million |
| 2008 | -767.99% | -1125.69% | 0.31x | 2.20x | GBX-10.40 Million |
| 2009 | -359.59% | -470.77% | 0.37x | 2.05x | GBX-4.72 Million |
| 2010 | -1166.60% | -212.46% | 0.60x | 9.08x | GBX-3.28 Million |
| 2017 | 0.00% | -1561.65% | 0.07x | 0.00x | GBX-5.78 Million |
| 2018 | 0.00% | -4465.42% | 0.08x | 0.00x | GBX-14.87 Million |
| 2019 | 0.00% | -3014.01% | 0.16x | 0.00x | GBX-11.38 Million |
| 2020 | 0.00% | -908.49% | 0.68x | 0.00x | GBX-12.89 Million |
| 2021 | -168.88% | -1949.59% | 0.08x | 1.15x | GBX-53.05 Million |
| 2022 | -166.37% | -3036.36% | 0.04x | 1.42x | GBX-20.54 Million |
| 2023 | -691.22% | -1198.00% | 0.21x | 2.75x | GBX-14.62 Million |
| 2024 | -277.71% | -932.06% | 0.16x | 1.86x | GBX-19.79 Million |
| 2025 | -848.01% | -1115.53% | 0.18x | 4.13x | GBX-29.94 Million |
Industry Comparison
This section compares Ondine Biomedical Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,460,727
- Average return on equity (ROE) among peers: -591.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ondine Biomedical Inc (OBI) | GBX3.49 Million | -5.26% | 3.13x | $916.61K |
| 4BASEBIO UK SOCIETAS (4BB) | $-492.00K | 0.00% | 0.00x | $989.13K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $172.28K |
| Arecor Therapeutics PLC (AREC) | $6.45 Million | 10.29% | 0.26x | $287.12K |
| Avacta Group PLC (AVCT) | $21.00K | -5252.38% | 9.24x | $3.89 Million |
| BSF Enterprise Plc (BSFA) | $4.86 Million | -30.89% | 0.08x | $17.57K |
| Bioventix (BVXP) | $6.58 Million | 38.84% | 0.05x | $1.11 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $937.00K | -418.46% | 0.23x | $135.04K |
| Amur Minerals Corporation (CRTX) | $22.23 Million | -6.94% | 0.04x | $64.52K |
| Fusion Antibodies PLC (FAB) | $1.12 Million | -231.17% | 0.84x | $172.86K |
| Faron Pharmaceuticals Oy (FARN) | $-15.16 Million | 0.00% | 0.00x | $602.85K |
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more